Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 508

1.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6.

2.
3.

TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.

Dong J, Xiao L, Sheng L, Xu J, Sun ZQ.

Asian Pac J Cancer Prev. 2014;15(7):3099-103.

4.

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.

Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.

Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 29.

5.

Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.

Winnes M, Lissbrant E, Damber JE, Stenman G.

Oncol Rep. 2007 May;17(5):1033-6.

PMID:
17390040
6.

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.

Neoplasia. 2006 Oct;8(10):885-8.

7.

[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].

Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB.

Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73. Chinese.

PMID:
18642766
8.
9.

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150. Epub 2010 Aug 6.

10.

TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y.

Tumour Biol. 2016 Sep;37(9):12397-12402. Epub 2016 Jun 20. Erratum in: Tumour Biol. 2016 Oct;37(10 ):14331.

PMID:
27320318
11.

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.

J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096. Epub 2010 Mar 19.

PMID:
20303538
12.

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB.

Mod Pathol. 2009 Sep;22(9):1176-85. doi: 10.1038/modpathol.2009.79. Epub 2009 May 22.

13.

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.

Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.

Anticancer Res. 2016 Sep;36(9):4787-93.

PMID:
27630329
14.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.

15.

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA.

Cancer Res. 2009 Apr 1;69(7):2734-8. doi: 10.1158/0008-5472.CAN-08-4926. Epub 2009 Mar 17.

16.

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M.

Prostate. 2011 Apr;71(5):489-97. doi: 10.1002/pros.21265. Epub 2010 Sep 28.

PMID:
20878952
17.

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O.

Cancer Res. 2006 Nov 1;66(21):10242-6.

18.

Androgen regulation of ETS gene fusion transcripts in prostate cancer.

Gasi D, Trapman J.

Methods Mol Biol. 2011;776:335-48. doi: 10.1007/978-1-61779-243-4_19.

PMID:
21796535
19.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

20.

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.

Supplemental Content

Support Center